Capivasertib + Palbociclib + Fulvestrant for HR+/HER2- Advanced Breast Cancer (CAPItello-292). - CAPItello-292

Study identifier:D361DC00001

ClinicalTrials.gov identifier:NCT04862663

EudraCT identifier:N/A

CTIS identifier:N/A

Recruiting

Official Title

A Phase Ib/III Randomised Study of Capivasertib plus Palbociclib and Fulvestrant versus Placebo plus Palbociclib and Fulvestrant in Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced, Unresectable or Metastatic Breast Cancer

Medical condition

Locally advanced (inoperable) or Metastatic Breast Cancer

Phase

Phase 3

Healthy volunteers

Study drug

Capivasertib, Matched Capivasertib Placebo, Fulvestrant, Palbociclib

Sex

All

Estimated Enrollment

700

Study type

Interventional

Age

18 Years - 99 Years

Date

Study Start Date: 10 May 2021

Estimated Primary Completion Date: 11 Feb 2026

Estimated Study Completion Date: 21 Apr 2028

Study design

Allocation: Randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 Nov 2022 by AstraZeneca

Collaborators

Inclusion and exclusion criteria

Inclusion Criteria

for both phases:
1. Adult females (pre- and/or post-menopausal), and adult males.
2. Histologically confirmed HR+/ HER2- breast cancer determined from the most recent tumour sample (primary or metastatic) per the American Society of Clinical Oncology and College of American Pathologists guideline. To fulfil the requirement of HR+ disease, a breast cancer must express ER with or without co-expression of progesterone receptor.
3. Eligible for palbociclib and fulvestrant therapy as per investigator assessment. Previous tolerance to specific CDK4/6 inhibitors and dose levels required.
4. Adequate organ and bone marrow functions.
5. Consent to provide a mandatory FFPE tumour sample.
Inclusion criteria only for phase III:
1. Previous treatment with an ET (tamoxifen or an AI) as a single agent or in combination, with:
a. radiological evidence of breast cancer recurrence or progression while on, or within 12 months of, completing a (neo)adjuvant ET regimen
OR
b. radiological evidence of progression while receiving the ET for locally advanced or metastatic breast cancer (this does not need to be the most recent therapy)
2. Received up to a maximum of 1 lines of prior chemotherapy in the advanced setting.
Key

Exclusion Criteria

for both phases:
1. History of another primary malignancy except for malignancy treated with curative intent with no known active disease ≥ 5 years before the first dose of study intervention and of low potential risk for recurrence.
2. Radiotherapy with a wide field of radiation within 4 weeks prior to study treatment initiation and/or radiotherapy with a limited field of radiation for palliation within 2 weeks prior to study treatment initiation. Patients who received prior radiotherapy to ≥25% of bone marrow are not eligible independent of when it was received.
3. Major surgery (excluding placement of vascular access) within 4 weeks of the first dose of study treatment.
4. Persistent toxicities (CTCAE Grade >1) caused by previous anticancer therapy, excluding alopecia. Participants with irreversible toxicity that is not reasonably expected to be exacerbated by study intervention may be included (eg, hearing loss) after consultation with the AstraZeneca study physician.
5. Spinal cord compression, brain metastases or leptomeningeal metastases unless asymptomatic, treated and stable and not requiring steroids within 4 weeks prior to study treatment initiation.
6. Any of the following cardiac criteria at screening:
(a). Mean resting corrected QT interval (QTc) > 470 msec obtained from 3 consecutive ECGs
(b). Any clinically important abnormalities in rhythm, conduction or morphology of resting ECG (eg, complete left bundle branch block, third-degree heart block)
(c). Any factors that increase the risk of QTc prolongation or risk of arrhythmic events
(d). Experience of any of the following procedures or conditions in the preceding 6 months: coronary artery bypass graft, angioplasty, vascular stent, myocardial infarction, angina pectoris, congestive heart failure New York Heart Association (NYHA) grade ≥ 2
(e). Uncontrolled hypotension
(f). Cardiac ejection fraction outside institutional range of normal or < 50% (whichever is higher)
7. Any of these clinically significant abnormalities of glucose metabolism at screening:
(a). diabetes mellitus type I or type II requiring insulin treatment
(b). HbA1c ≥ 8.0% (63.9 mmol/mol)
8. Previous allogeneic bone marrow transplant or solid organ transplant.
Key exclusion criteria for the phase III only:
1. Any prior treatment with SERDs, AKT, PI3K or mTOR inhibitors.
2. Prior treatment with CDK4/6 inhibitors in the metastatic setting (prior CDK4/6 inhibitors permitted in the adjuvant setting).

Sort by status

No locations available

Arms	Assigned Interventions
Experimental: Capivasertib Plus Palbociclib and Fulvestrant Capivasertib Plus Palbociclib and Fulvestrant	Drug: Capivasertib Phase Ib: Capivasertib 320 mg, administered PO BD 4 days on /3 days off per week for 4 weeks (28 days cycle) Phase III: : Capivasertib, administered PO BD 4 days on / 3 days off per week for 4 weeks (28 days cycle) at the dose confirmed in the phase Ib portion Drug: Fulvestrant Phase Ib and Phase III: 500 mg (2 injections of 250 mg) on Day 1 of Weeks 1 and 3 of Cycle 1, and then on Day 1, Week 1 of each cycle thereafter Drug: Palbociclib Phase Ib: Potential range 75 mg, 100 mg, 125 mg. Once daily for 21 consecutive days followed by 7 days off treatment to comprise a complete 28-day cycle Phase III: Administrated once daily for 21 days of 28-day cycle), at the dose confirmed in the phase 1b portion
Placebo Comparator: Placebo Plus Palbociclib and Fulvestrant Placebo Plus Palbociclib and Fulvestrant	Drug: Matched Capivasertib Placebo Phase Ib: Not applicable Phase III: Administrated BD 4 days on 3 days off/week for 4 weeks, at the dose confirmed in the phase Ib portion Drug: Fulvestrant Phase Ib and Phase III: 500 mg (2 injections of 250 mg) on Day 1 of Weeks 1 and 3 of Cycle 1, and then on Day 1, Week 1 of each cycle thereafter Drug: Palbociclib Phase Ib: Potential range 75 mg, 100 mg, 125 mg. Once daily for 21 consecutive days followed by 7 days off treatment to comprise a complete 28-day cycle Phase III: Administrated once daily for 21 days of 28-day cycle), at the dose confirmed in the phase 1b portion

Arms

Assigned Interventions

Experimental: Capivasertib Plus Palbociclib and Fulvestrant
Capivasertib Plus Palbociclib and Fulvestrant

Drug: Capivasertib
Phase Ib: Capivasertib 320 mg, administered PO BD 4 days on /3 days off per week for 4 weeks (28 days cycle) Phase III: : Capivasertib, administered PO BD 4 days on / 3 days off per week for 4 weeks (28 days cycle) at the dose confirmed in the phase Ib portion

Drug: Fulvestrant
Phase Ib and Phase III: 500 mg (2 injections of 250 mg) on Day 1 of Weeks 1 and 3 of Cycle 1, and then on Day 1, Week 1 of each cycle thereafter

Drug: Palbociclib
Phase Ib: Potential range 75 mg, 100 mg, 125 mg. Once daily for 21 consecutive days followed by 7 days off treatment to comprise a complete 28-day cycle Phase III: Administrated once daily for 21 days of 28-day cycle), at the dose confirmed in the phase 1b portion

Placebo Comparator: Placebo Plus Palbociclib and Fulvestrant
Placebo Plus Palbociclib and Fulvestrant

Drug: Matched Capivasertib Placebo
Phase Ib: Not applicable Phase III: Administrated BD 4 days on 3 days off/week for 4 weeks, at the dose confirmed in the phase Ib portion

Drug: Fulvestrant
Phase Ib and Phase III: 500 mg (2 injections of 250 mg) on Day 1 of Weeks 1 and 3 of Cycle 1, and then on Day 1, Week 1 of each cycle thereafter

Documents available

BreastCancerStudyLocator.com
Download
Trial Results Summaries
Available here

Contacts

Contact

AstraZeneca Clinical Study Information Center

1-877-240-9479

[email protected]

Contact Backup

AZ Breast Cancer Study Navigators

+1-877-400-4656